A recent cost-effectiveness analysis evaluated treatments for relapsed or refractory multiple myeloma from a United States health system perspective. READ MORE

News

In patients with multiple myeloma, minimal residual disease detected by next-generation sequencing after autologous-HSCT has significant prognostic value.

READ MORE